Cantor Fitzgerald maintains an Overweight rating on Vaxcyte, with Gould explaining the firm's position amid ACIP meeting effects.
1 report, 0 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald maintains an Overweight rating on Vaxcyte, with Gould explaining the firm's position amid ACIP meeting effects.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Gould
Nothing else this week.
Related events
- Cantor Fitzgerald reiterated its 'overweight' rating on Oracle stock on June 11, 2026.
- Cantor Fitzgerald restated an overweight rating for MoonLake Immunotherapeutics, which trades on Nasdaq, with data provided by MarketBeat.
- Cantor Fitzgerald restated an overweight rating and Royal Bank of Canada reduced its price objective for United Therapeutics.
- Cantor Fitzgerald and Sarah James lowered price targets on Centene Corporation.
- Cantor Fitzgerald and Citigroup restated positive rating upgrades for Sagimet Biosciences.
Coverage
Newest first; wire copies grouped- Unknown outlet